Pasithea Therapeutics Adds Esketamine Nasal Spray to its Clinic Offerings in the U.K.
November 23 2021 - 8:00AM
Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the
“Company”), a novel biotechnology company focused on the research
and discovery of new and effective treatments for psychiatric and
neurological disorders, today announced that its wholly owned
subsidiary, Pasithea Clinics, has been approved to provide
esketamine nasal spray (SPRAVATO®) for treatment-resistant
depression in adults, and has begun offering the treatment in its
Knightsbridge, London location. Only three clinics in the U.K. have
been accredited to offer this treatment.
“This is an important milestone for our U.K.
clinics and their patients,” stated Dr. Tiago Reis Marques, CEO of
Pasithea Therapeutics. “Major Depression is the leading cause of
long-term disability worldwide. Current treatments have limited
success and up to 30% of patients with depression do not respond to
consecutive trials of antidepressant treatment. These patients are
considered to have treatment-resistant depression and new treatment
options are urgently needed.”
“Esketamine is safe and effective, especially
when combined with ongoing psychiatric support. Due to some risks
associated with this drug, patients treated in outpatient settings
must be enrolled in a specific program. We are extremely proud to
have been accredited to provide this treatment, a reflection of our
high standards of care,” said Dr. Yassine Bendiabdallah, Managing
Director of Pasithea Clinics in the U.K.
About SPRAVATO®
SPRAVATO® (esketamine) CIII nasal spray is a
non-selective, non-competitive antagonist of the
N-methyl-D-aspartate (NMDA) receptor – an ionotropic glutamate
receptor. It has a novel mechanism of action, meaning it works
differently than currently available therapies for major depressive
disorder (MDD).
SPRAVATO® is approved in the United States, in
conjunction with an oral antidepressant, to treat adults with
treatment-resistant depression (TRD) and depressive symptoms in
adults with MDD with acute suicidal ideation or behavior. SPRAVATO®
has been submitted for health authorities’ review for TRD and
adults with MDD who have current suicidal ideation with intent in
other markets around the world, including Europe.
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corporation is a U.S.
biotechnology company focused on the research and discovery of new
and effective treatments for psychiatric and neurological
disorders. With an experienced team of experts in the fields of
neuroscience and psychopharmacology, Pasithea is developing new
molecular entities for the treatment of psychiatric and
neurological disorders. Pasithea is also focused on addressing the
needs of patients currently suffering with mental illness by
providing access to IV ketamine infusions both in clinics and
in-home settings.
Forward Looking Statements
This press release contains statements that
constitute “forward-looking statements.” Forward-looking statements
are subject to numerous conditions, many of which are beyond the
control of the Company. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to the Company on the date of this
release. These forward-looking statements are based upon current
estimates and assumptions and are subject to various risks and
uncertainties, including, without limitation, those set forth in
the Company’s filings with the SEC. Thus, actual results could be
materially different. The Company undertakes no obligation to
update these statements whether as a result of new information,
future events or otherwise, after the date of this release, except
as required by law.
Pasithea Therapeutics Corp. Company Contact
Dr. Tiago Reis MarquesChief Executive OfficerE:
tiago@pasithea.com
Pasithea Therapeutics Corp. Investor
Relations
Lisa M. WilsonIn-Site Communications, Inc.T: 212-452-2793E:
lwilson@insitecony.com
Pasithea Therapeutics (NASDAQ:KTTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pasithea Therapeutics (NASDAQ:KTTA)
Historical Stock Chart
From Apr 2023 to Apr 2024